WINNIPEG, Manitoba - (May 28, 2004) - Medicure
Inc. (TSX:MPH/Amex:MCU), a cardiovascular drug discovery and development
company, is pleased to announce that it has been accepted to present
as part of the Business Forum of BIO 2004, the world's largest biotechnology
conference. The Business Forum at BIO 2004 is a platform where investors
and pharmaceutical executives will have the opportunity to hear
from biotechnology companies located around the world. The Annual
Convention takes place June 6 - 9, 2004, in San Francisco, California.
The Medicure presentation will be made by President and Chief Executive
Officer, Dr. Albert D. Friesen, Ph.D, and will take place at 10:45
am (Pacific Time) on Tuesday, June 8, 2004.
"As we know from our previous experience, BIO 2004 is an exciting
venue for us to present the Medicure story," said Dr. Friesen.
"It is another opportunity for us to raise Medicure's profile
on the international stage, and our participation in this conference
reflects a growing recognition of Medicure, its products, technology
and management team."
A key component of the Business Forum, in addition to the corporate
presentation, is the opportunity for presenting companies to schedule
one-on-one meetings with representatives of pharmaceutical, biotechnology
and other healthcare-focused companies, along with members of the
financial community and the media.
Now in its 11th year, BIO has grown significantly since its inception,
with approximately 20,000 delegates, including biotech executives,
politicians, scientists, industry officials and potential investors
expected at the four-day conference.
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on the prevention and treatment of ischemia, ischemic
reperfusion injury, and stroke. The cardiovascular and stroke market
is the largest pharmaceutical sector with annual global sales of
over US $70 billion.
The Company's second product candidate, MC-4232, is being targeted
for the treatment of hypertension, a common disorder in which blood
pressure remains abnormally high. Approximately 73% of the more
than 50 million adult Americans who have hypertension, are not adequately
treated.
Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule, anti-ischemics
and anti-thrombotics towards human clinical studies.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
